CHIMERIC ANTI-CD4 WITHOUT CONCOMITANT DMARD THERAPY IN RHEUMATOID ARTHRITIS

类风湿性关节炎中不伴随 DMARD 治疗的嵌合抗 CD4

• 批准号: 3783437
• 负责人: EUGENE W ST CLAIR
• 金额: --
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3783437
• 关键词: CD4 molecule; antiarthritic agent; clinical trials; drug administration rate /duration; drug screening /evaluation; human subject; hybrid antibody; placebos; rheumatoid arthritis

The purpose of this study is to obtain placebo-controlled data on the clinical response and safety to three dose levels of chimeric ant-CD4 antibody when administered daily for five consecutive days in patients with Rheumatoid Arthritis.

本研究的目的是获得安慰剂对照数据， 对三种剂量水平的嵌合ant-CD 4的临床应答和安全性 当患者连续5天每天给药时， 患有类风湿性关节炎。